Norfolk and Norwich University Hospital

Running trials

• Not yet recruiting

  Adalimumab Dose Adjustment for Pediatric Uveitis Treatment Trial

  NCT07699107· Phase 4· Nisha Acharya· Source

• Recruiting

  A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

  NCT07393282· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT07499232· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  NCT07361510· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis

  NCT07230288· Phase 2· AbbVie· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

  NCT05093231· Phase 2· Cambridge University Hospitals NHS Foundation Trust· Source

• Active, not recruiting

  WATER IV Prostate Cancer

  NCT06651632· PROCEPT BioRobotics· Source

• Active, not recruiting

  StatSeal vs Figure-of-Eight Suture for Vascular Closure in AF Ablation

  NCT06627959· Mid and South Essex NHS Foundation Trust· Source

• Recruiting

  Closed-loop in Adults With Type 2 Diabetes

  NCT06579404· University of Cambridge· Source

• Active, not recruiting

  EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT06425991· Phase 1· Janssen Research & Development, LLC· Source

• Recruiting

  Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)

  NCT06295731· Phase 2/3· Inhibrx Biosciences, Inc· Source

• Recruiting

  A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

  NCT06091254· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06132256· Phase 2· Syndax Pharmaceuticals· Source

• Active, not recruiting

  Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma

  NCT05004064· Phase 2· University College, London· Source

• Recruiting

  Liquid Biopsy System Intracoronary Blood Sampling and Analysis to Characterise Disease Biomarkers in Patients With Coronary Disease

  NCT06259019· PlaqueTec Ltd· Source

• Active, not recruiting

  CGM Use in Adults With Type 2 Diabetes on Basal Insulin

  NCT05944432· Abbott Diabetes Care· Source

• Active, not recruiting

  Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)

  NCT05817942· Alfasigma S.p.A.· Source

• Active, not recruiting

  A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis

  NCT05785611· Phase 3· Alfasigma S.p.A.· Source

• Recruiting

  A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).

  NCT05608681· Phase 1/2· Eupraxia Pharmaceuticals Inc.· Source

• Active, not recruiting

  A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

  NCT05572515· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)

  NCT04939935· Phase 3· The University of Queensland· Source

• Recruiting

  Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

  NCT04685616· Phase 3· University College, London· Source

• Recruiting

  Hemithyroidectomy or Total-Thyroidectomy in 'Low-risk' Thyroid Cancers

  NCT05604963· University College, London· Source

• Active, not recruiting

  Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)

  NCT04546620· Phase 2· University Hospital Southampton NHS Foundation Trust· Source

• Active, not recruiting

  The SELUTION DeNovo Study

  NCT04859985· M.A. Med Alliance S.A.· Source

• Recruiting

  Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk

  NCT04774159· Phase 3· Population Health Research Institute· Source

• Active, not recruiting

  Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

  NCT04666038· Phase 3· Loxo Oncology, Inc.· Source

• Recruiting

  The Early Valve Replacement in Severe ASYmptomatic Aortic Stenosis Study

  NCT04204915· University of Leicester· Source

• Recruiting

  MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera

  NCT04116502· Phase 3· University of Birmingham· Source

• Active, not recruiting

  A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome

  NCT03899337· Phase 2· University of Birmingham· Source

• Active, not recruiting

  A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

  NCT03811561· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

  NCT03900429· Phase 3· Madrigal Pharmaceuticals, Inc.· Source

• Active, not recruiting

  Outcomes of Drug Coated Balloon Angioplasty, A UK Real Life Experience From 2009 to 2015

  NCT03603210· Norfolk and Norwich University Hospitals NHS Foundation Trust· Source

• Recruiting

  The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)

  NCT03562169· Phase 3· University of Leeds· Source

• Active, not recruiting

  Study of Tumour Focused Radiotherapy for Bladder Cancer

  NCT02447549· Phase 2· Institute of Cancer Research, United Kingdom· Source

• Active, not recruiting

  CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)

  NCT04116047· Phase 3· University of Birmingham· Source

• Active, not recruiting

  MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma

  NCT02385214· Melanoma and Skin Cancer Trials Limited· Source

• Active, not recruiting

  Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer

  NCT01566240· Phase 3· University College, London· Source

• Active, not recruiting

  Prostate Advances in Comparative Evidence

  NCT01584258· Phase 3· Royal Marsden NHS Foundation Trust· Source

• Active, not recruiting

  Minimal SN Tumor Burden

  NCT01942603· European Organisation for Research and Treatment of Cancer - EORTC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers2 recruiting
• Coronary artery disease2 recruiting
• Heart failure2 recruiting
• Multiple myeloma2 recruiting
• Type 2 diabetes2 recruiting
• Aortic stenosis1 recruiting
• Crohn's disease1 recruiting
• Eosinophilic oesophagitis1 recruiting
• Follicular lymphoma1 recruiting
• High blood pressure1 recruiting
• Hodgkin lymphoma1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Lung cancer1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Obesity1 recruiting
• Peripheral artery disease1 recruiting
• Polycystic kidney disease1 recruiting
• Stroke1 recruiting
• Thyroid cancer1 recruiting

Closed trials

• Completed

  The Role of SGLT2i in Management of Moderate AS

  NCT06469645· Phase 2/3· University of East Anglia· Source

• Completed

  DELIVER Study in a Population With Clinical Suspicion of Liver Cirrhosis

  NCT07035158· Owlstone Ltd· Source

• Completed

  Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF

  NCT06331624· Phase 2· GRI Bio Operations, Inc.· Source

• Completed

  Cough Reduction in IPF With Nalbuphine ER

  NCT05964335· Phase 2· Trevi Therapeutics· Source

• Completed

  A Study of CDX-0159 in Patients With Eosinophilic Esophagitis

  NCT05774184· Phase 2· Celldex Therapeutics· Source

• Completed

  A Phase 2 Placebo Controlled, Clinical Trial Designed to Assess the Efficacy, Safety and Dose Response Characterisation of STS01 for the Treatment of Mild-moderate Alopecia Areata (AA)

  NCT06402630· Phase 2· Soterios Ltd· Source

• Completed

  Adalimumab in JIA-associated Uveitis Stopping Trial

  NCT03816397· Phase 4· Nisha Acharya· Source

• Terminated

  NOLA (NeuWave Observational Liver Ablation) Registry

  NCT04107766· Ethicon, Inc.· Source

• Completed

  AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC

  NCT04006405· Elypta· Source

• Completed

  CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)

  NCT04226248· Phase 3· University of Bristol· Source

• Completed

  A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

  NCT03914326· Phase 3· Novo Nordisk A/S· Source

• Completed

  EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

  NCT03594110· Phase 3· Boehringer Ingelheim· Source

• Completed

  Multiple Sclerosis-Simvastatin Trial 2

  NCT03387670· Phase 3· University College, London· Source

• Completed

  Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry

  NCT03048825· Phase 3· Population Health Research Institute· Source

• Completed

  A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant

  NCT03106324· Celgene· Source

• Completed

  Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

  NCT02947347· Phase 3· Pharmacyclics LLC.· Source

• Completed

  Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke

  NCT02898610· Phase 3· University College Dublin· Source

• Completed

  A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease

  NCT02620046· Phase 3· Takeda· Source

• Completed

  Non-interventional Study to Evaluate Long Term Safety, Prescription Management Patterns of Esmya in a Long Term Setting

  NCT02748460· PregLem SA· Source

• Completed

  Evaluation of Groin Lymphadenectomy Extent For Metastatic Melanoma

  NCT02166788· Phase 3· Melanoma and Skin Cancer Trials Limited· Source

• Completed

  Stereotactic Radiotherapy for Wet AMD (STAR)

  NCT02243878· Phase 3· King's College Hospital NHS Trust· Source

• Completed

  Trial of 1 Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Testis Tumours

  NCT01726374· Phase 3· Institute of Cancer Research, United Kingdom· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Polymyalgia rheumatica6 works · 0 trials
• Giant cell arteritis5 works · 0 trials